Tapering subcutaneous methotrexate causes more disease flares compared with tapering oral administration in established rheumatoid arthritis patients

Rheumatology (Oxford). 2022 Aug 3;61(8):e216-e218. doi: 10.1093/rheumatology/keac154.

Authors

Agnes E M Looijen¹, Elise van Mulligen^{1

2}, Annette H M van der Helm-van Mil^{1

2}, Pascal H P de Jong¹

Affiliations

¹ Department of Rheumatology, Erasmus University Medical Centre, Rotterdam.
² Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.

PMID: 35266525
DOI: 10.1093/rheumatology/keac154

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Humans
Injections, Subcutaneous
Methotrexate / therapeutic use
Symptom Flare Up

Substances

Antirheumatic Agents
Methotrexate